Dostralimab in Rectal Cancer: A Comprehensive Review

Registration ID: IJNRD_182338

Published ID: IJNRD2208026

DOI: Click Here to Get

Akhila Bollam , Harshini Kancherla , Priyanka Patlolla , Vyshnavi Bodla , Ramya Bala Prabha G

Rectal Cancer, Dostarlimab, Jemperli, Chemotherapy, Immune checkpoint inhibitors.

Cancer is a large group of diseases that can start in almost any organ or tissue of the body. Rectal wall is made up of layers of tissue. Cancer begins in the innermost layer that comes in touch with food. Dostarlimab is a humanized monoclonal antibody that is developed for the treatment of various cancers. Brand name of Dostarlimab is jemperli. Dosage of Dostarlimab in adults include Dose 1 through 4 of jemperli is 500mg every 3weeks. Common side effects of Dostarlimab may include abnormal liver function tests, nausea, diarrhoea, constipation, low white blood cell counts, anaemia, or feeling weak or tired. Dostarlimab belong to class of drugs called anti-programmed cell death-1 (PD-1) monoclonal antibodies, immune checkpoint inhibitors, programmed death-ligand 1 (PD-L1) blocking antibodies. This drug was initially tried in treating uterine cancer and it was found to be effective. The recent study by the memorial Sloan Kettering cancer centre, New York, is the first clinical investigation that shown its effectiveness against rectal cancer. In the trial patients had stage II or III cancer and drug was given every three weeks for six months. The trial shown dramatic results that there are no apparent signs of tumour after at least follow-up for six months in rectal cancer patients. Locally advanced rectal cancer is usually managed by neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum. Recent evidence suggests that use of neoadjuvant therapy in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin followed by chemotherapy and then surgery.In recent clinical trial Dostarlimab is used for rectal cancer and it shown prominent result. But longer follow-up is needed to assess the drug drug whether disease cautious to be uncontrolled or whether the drug is safe.

Published Paper   E-Certificate

Akhila Bollam, Harshini Kancherla, Priyanka Patlolla, Vyshnavi Bodla, & Ramya Bala Prabha G (August-2022). Dostralimab in Rectal Cancer: A Comprehensive Review. INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT, 7(8), 233-238. https://ijnrd.org/papers/IJNRD2208026.pdf

Volume 7 Issue 8, August-2022

Pages : 233-238

Paper Reg. ID: IJNRD_182338

Published Paper Id: IJNRD2208026

Downloads: 000121985

Research Area: Pharmacy

Country: Hyderabad, Telangana, India

Published Paper PDF: https://ijnrd.org/papers/IJNRD2208026.pdf

Published Paper URL: https://ijnrd.org/viewpaperforall?paper=IJNRD2208026

Journal Name: INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT(IJNRD)

ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar | ESTD YEAR: 2016

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Publisher: IJNRD (IJ Publication) Janvi Wave | IJNRD.ORG | IJNRD.COM | IJPUB.ORG

This work is licensed under a Creative Commons Attribution 4.0 International License and The Open Definition

Call For Paper - Volume 10 | Issue 10 | October 2025

IJNRD is a Scholarly Open Access, Peer-reviewed, and Refereed Journal with a High Impact Factor of 8.76 (calculated by Google Scholar & Semantic Scholar | AI-Powered Research Tool). It is a Multidisciplinary, Monthly, Low-Cost Journal that follows UGC CARE 2025 Peer-Reviewed Journal Policy norms, Scopus journal standards, and Transparent Peer Review practices to ensure quality and credibility. IJNRD provides indexing in all major databases & metadata repositories, a citation generator, and Digital Object Identifier (DOI) for every published article with full open-access visibility.

The INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) aims to advance applied, theoretical, and experimental research across diverse fields. Its goal is to promote global scientific information exchange among researchers, developers, engineers, academicians, and practitioners. IJNRD serves as a platform where educators and professionals can share research evidence, models of best practice, and innovative ideas, contributing to academic growth and industry relevance.

Indexing Coverage includes Google Scholar, SSRN, ResearcherID-Publons, Semantic Scholar (AI-Powered Research Tool), Microsoft Academic, Academia.edu, arXiv.org, ResearchGate, CiteSeerX, ResearcherID (Thomson Reuters), Mendeley, DocStoc, ISSUU, Scribd, and many more recognized academic repositories.

How to submit the paper?

By Our website

Click Here to Submit Paper Online

By Mail

Send your paper to editor@ijnrd.org

Important Dates for Current issue

Paper Submission Open For: October 2025

Current Issue: Volume 10 | Issue 10 | October 2025

Impact Factor: 8.76

Last Date for Paper Submission: Till 31-Oct-2025

Notification of Review Result: Within 1-2 Days after Submitting paper.

Publication of Paper: Within 01-02 Days after Submititng documents.

Frequency: Monthly (12 issue Annually).

Journal Type: IJNRD is an International Peer-reviewed, Refereed, and Open Access Journal with Transparent Peer Review as per the new UGC CARE 2025 guidelines, offering low-cost multidisciplinary publication with Crossref DOI and global indexing.

Subject Category: Research Area

Call for Paper: More Details